Precancerous conditions after H. pylori eradication: A randomized double blind study in first degree relatives of gastric cancer patients

Archives of Iranian Medicine

Volumn 15, Issue 11, 2012, Pages 664-669

  Massarrat, Sadegh ^a   Haj Sheykholeslami, Arghavan ^a   Mohamadkhani, Ashraf ^a   Zendehdel, Nasrin ^b   Rakhshani, Naser ^a   Stolte, Manfred ^c   Mirzaei, Mahboobeh ^a   Saliminejhad, Mehrdad ^a   Saeidi, Sandra ^d   Shahidi, Mehdi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Klinikum Kulmbach   (Germany)

^d AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

H. pylori eradication; Precancerous lesions; Randomized trial

Indexed keywords

BISMUTH CITRATE; FURAZOLIDONE; METRONIDAZOLE; PLACEBO; RANITIDINE;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER PATIENT; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ERADICATION THERAPY; FEMALE; FIRST DEGREE RELATIVE; FOLLOW UP; GASTROSCOPY; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRECANCER; RANDOMIZED CONTROLLED TRIAL; RELATIVE; STOMACH ANTRUM; STOMACH ATROPHY; STOMACH CANCER;

ADULT; AGED; CARDIA; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METAPLASIA; MIDDLE AGED; PRECANCEROUS CONDITIONS; PYLORIC ANTRUM; STOMACH NEOPLASMS;

EID: 84868231450     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani Pl. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009; 151: 121-128.
3. Witteman EM. Mravunac M, Becx MJ, Hopman WP. Verschoor JS, Tytgat GN, et al. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori. JClin Pathol. 1995; 48: 250-256.
4. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a highrisk region of China: a randomized controlled trial. JAMA. 2004; 291: 187-194.
5. van der Hulst RW, van der Ende A, Dekker FW, Ten Kate FJ, Weel JF, Keller JJ, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997; 113: 25-30.
6. Tepes B, Kavcic B, Zaletel LK, Gubina M, Ihan A, Poljak M, et al. Two-to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol. 1999; 188: 24-29.
7. Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter. 1998; 3: 236-240.
8. Kyzekova J, Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology. 1999; 46: 2048-2056.
9. Vannella L, Lahner E, Bordi C, Pilozzi E, Di Giulio E, Corleto VD, et al. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. Dig Liver Dis. 2011; 43: 295-299.
10. Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000; 119: 7-14.
11. Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol. 1996; 11: 670-673.
12. Lahner E, Bordi C, Cattaruzza MS, Iannoni C, Milione M, Delle Fave G, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005; 22: 471-481.
13. Ciok J, Dzieniszewski J, Lucer C. Helicobacter pylori eradication and antral intestinal metaplasia--two years follow-up study. J Physiol Pharmacol. 1997; 48(suppl 4): 115-122.
14. Kim N, Lim SH, Lee KH, Choi SE, Jung HC, Song IS, et al. Longterm effects of Helicobacter pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers. Dig Dis Sci. 2000; 45: 1754-1762.
15. Kokkola A, Sipponen P, Rautelin H, Härkönen M, Kosunen TU, Haapiainen R, et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther. 2002; 16: 515-520.
16. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006; 98: 974-983.
17. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow-up of patients treated for Helicobacter pylori infection. Gut. 2005; 54: 1536-1540.
18. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92: 1881-1888.
19. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther. 2004; 19: 1181-1188.
20. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011; 83: 253-260.
21. Lee YC. Chen TH, Cliiu HM, Shun CT. Chiang K Liu TY: et al. The benefit of mass eradication of Helicobacter pylori infection: a commu-nity-based study of gastric cancer prevention. Gut. 2012;[Epub ahead Print].
22. Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012; 61: 812-818.
23. Lehtola J. Family study of gastric carcinoma; With special reference to histological types. Scand J Gastroenterol Suppl. 1978; 50: 3-54.
24. Meining A, Bayerdörffer E, Müller P, Miehlke S, Lehn N, Hölzel D, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998; 432: 311-314.
25. Kodama M, Murakami K, Okimoto T, Abe T, Nakagawa Y, Mizukami K, et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 2012; 85: 126-130.
26. Koivisto TT, Voutilainen ME, Farkkila MA. Effect of smoking on gastric histology in Helicobacter pylori-positive gastritis. Scand J Gastroenterol. 2008; 43: 1177-1183.
27. Jedrychowski W, Popiela T, Drews M, Gabryelewicz A, Marlicz K, Misiunia P, et al. Effect of Helicobacter pylori infection, smoking and dietary habits on the occurrence of antrum intestinal metaplasia. Clinico-epidemiological study in Poland. Pol J Pathol. 1999; 50: 289-295.
28. Peleteiro B, Lunet N, Figueiredo C, Carneiro F, David L, Barros H. Smoking, Helicobacter pylori virulence, and type of intestinal metaplasia in Portuguese males. Cancer Epidemiol Biomarkers Prev. 2007; 16: 322-326.
29. Dias-Neto M, Pintalhao M, Ferreira M, Lunet N. Salt intake and risk of gastric intestinal metaplasia: systematic review and meta-analysis. Nutr Cancer. 2010; 62: 133-147.
30. Chen VW, Abu-Elyazeed RR, Zavala DE, Ktsanes VK, Haenszel W, Cuello C, et al. Risk factors of gastric precancerous lesions in a highrisk Colombian population. I. Salt. Nutr Cancer. 1990; 13: 59-65.
31. Offerhaus GJ, Price AB, Haot J, ten Kate FJ, Sipponen P, Fiocca R, et al. Observer agreement on the grading of gastric atrophy. Histopathology. 1999; 34: 320-325.
32. Rugge M. Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol They. 2002:16: 1249-1259.
33. Ell C, Schoerner C, Solbach W, Stolte M, Vieth M, Ridl W, et al. The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 2001; 13: 685-691.